NuVasive (NUVA) stock is expected to deviate a maximum of $5.05 from the average target price of $69.55 for the short term period. 11 Street Experts have initiated coverage on the stock with the most promising target being $77 and the most muted being $58.
NuVasive (NUVA) : The consensus on NuVasive (NUVA) based on 14 analyst recommendation on the company stock is 1.29, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 1 which endorses a Strong Buy on the stock. However, 12 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Also, UBS maintains its rating on NuVasive (NASDAQ:NUVA). The global brokerage major raises the current price target from $60 per share to $71 per share. Analysts at the UBS have a current rating of Buy on the shares. The rating by the firm was issued on July 28, 2016.
NuVasive (NASDAQ:NUVA): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $65.47 and $64.65 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $66.08. The buying momentum continued till the end and the stock did not give up its gains. It closed at $66.06, notching a gain of 0.90% for the day. The total traded volume was 741,962 . The stock had closed at $65.47 on the previous day.
Nuvasive, Inc. is a global medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its marketed product portfolio is focused on applications for spine fusion surgery. Its product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The MAS platform combines three categories of solutions that collectively minimize soft tissue disruption during spine fusion surgery, provide visualization and are designed to enable reproducible outcomes for the surgeon and the patient. The platform includes the Companys software-driven nerve detection and avoidance systems, including NVM5 and NVJJB, Intra-Operative Monitoring (IOM) services and support; MaXcess, which is an integrated split-blade retractor system, and a variety of implants and biologics.